ArticleScientific reports2026
Pharmacological profiling of Gnetum gnemon var. tenerum extracts exhibits antibacterial, antioxidant, cytotoxic and anti-inflammatory activities.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study conducted a comprehensive in vitro pharmacological evaluation of the crude extract and solvent-partitioned fractions of Gnetum gnemon var. tenerum. LC-MS metabolite profiling identified 77 compounds, including flavonoids and phenylethanolamine derivatives, that exhibit the antioxidant, cytotoxic, and anti-inflammatory activities described in this paper. The total phenolic and flavonoid contents (TPC/TFC) were quantified, showed that the ethyl acetate and n-butanol fractions contained the highest levels of these phytochemicals. These fractions exhibited strong antioxidant activity in both ABTS and DPPH assays. The antibacterial activity of the extracts was assessed using disk diffusion, MIC, and MBC assays against five pathogenic bacteria, where the chloroform and ethyl acetate fractions demonstrated the highest potency, with MIC values as low as 0.049 mg/mL against Acinetobacter baumannii. Cytotoxicity testing on human gastrointestinal cancer cell lines (AGS, HT-29) and a normal intestinal epithelial cell line (HIEC-6) showed dose-dependent cytotoxicity toward cancer cells while exerting markedly lower effects on normal cells, suggesting selective action. Anti-inflammatory activity, evaluated by nitric oxide (NO) inhibition in LPS-stimulated RAW264.7 macrophages, revealed that the chloroform and ethyl acetate fractions most effectively suppressed NO production. These findings provide scientific support for the traditional uses of G. gnemon and highlight its extracts as a promising source of bioactive compounds with multi-target pharmacological potential against oxidative stress, bacterial infections, inflammation, and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.